Evaluation, Treatment, and Training for Patients With Blood Disorders
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00001397|
Recruitment Status : Completed
First Posted : November 4, 1999
Last Update Posted : October 8, 2020
This study is designed to allow the evaluation, follow-up, and medical care of patients with blood disorders not currently participating in a research study being conducted by the Hematology Branch of the National Heart, Lung and Blood Institute (NHLBI) or not being screened for participation in a study.
The purpose of this study is to allow investigation into the blood disorders of patients in order to teach, learn, and gather more information about diseases of the blood.
In addition, this study allows researchers the opportunity to evaluate patients referred to the Hematology Branch of the NHLBI with rare or undiagnosed diseases of the blood. This may be potentially beneficial to the patient and at the same time contribute to the development of new research ideas.
|Condition or disease|
|Study Type :||Observational|
|Actual Enrollment :||1452 participants|
|Official Title:||Evaluation, Treatment and Training Protocol for Patients With Bone Marrow Failure States, Isolated or Multilineage Cytopenias, Metastatic Solid Tumors, or Hematologic Malignancies|
|Actual Study Start Date :||November 8, 1993|
|Actual Primary Completion Date :||October 5, 2020|
|Actual Study Completion Date :||October 5, 2020|
treated according to the guidelines of standard medical evaluation and care. No investigational treatments or procedures will be administered on this protocol.
- To provide a mechanism for the evaluation, follow-up, and standard hematological care of patients by the Hematology Branch [ Time Frame: 20 years ]To provide a mechanism for the evaluation, follow-up, and standard hematological care of patients by the Hematology Branch
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00001397
|United States, Maryland|
|National Institutes of Health Clinical Center, 9000 Rockville Pike|
|Bethesda, Maryland, United States, 20892|
|Principal Investigator:||Georg Aue, M.D.||National Heart, Lung, and Blood Institute (NHLBI)|